Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

Next Previous
Trial Profile

A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IG 3018 (Primary)
  • Indications Hyperuricaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Intelligem Therapeutics Australia

Most Recent Events

  • 03 Feb 2026 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
  • 03 Feb 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jul 2026.
  • 12 Mar 2025 Planned number of patients changed from 46 to 60.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top